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PQUARTERLY FOCUS ISSUE: HEART FAILURE
Continuous Flow Left Ventricular Assist
Device Improves Functional Capacity and
Quality of Life of Advanced Heart Failure Patients
Joseph G. Rogers, MD,* Keith D. Aaronson, MD,† Andrew J. Boyle, MD,‡ Stuart D. Russell, MD,§
Carmelo A. Milano, MD,* Francis D. Pagani, MD,† Brooks S. Edwards, MD, Soon Park, MD,
Ranjit John, MD,‡ John V. Conte, MD,§ David J. Farrar, PHD,¶ Mark S. Slaughter, MD,#
for the HeartMate II Investigators
Durham, North Carolina; Ann Arbor, Michigan; Minneapolis and Rochester, Minnesota; Baltimore, Maryland;
Pleasanton, California; and Oak Lawn, Illinois
Objectives This study sought to assess the impact of continuous flow left ventricular assist devices (LVADs) on functional
capacity and heart failure-related quality of life.
Background Newer continuous-flow LVAD are smaller and quieter than pulsatile-flow LVADs.
Methods Data from advanced heart failure patients enrolled in the HeartMate II LVAD (Thoratec Corporation, Pleasanton,
California) bridge to transplantation (BTT) (n  281) and destination therapy (DT) (n  374) trials were ana-
lyzed. Functional status (New York Heart Association [NYHA] functional class, 6-min walk distance, patient activ-
ity scores), and quality of life (Minnesota Living With Heart Failure [MLWHF] and Kansas City Cardiomyopathy
Questionnaires [KCCQ]) were collected before and after LVAD implantation.
Results Compared with baseline, LVAD patients demonstrated early and sustained improvements in functional status
and quality of life. Most patients had NYHA functional class IV symptoms at baseline. Following implant, 82%
(BTT) and 80% (DT) of patients at 6 months and 79% (DT) at 24 months improved to NYHA functional class I or
II. Mean 6-min walk distance in DT patients was 204 m in patients able to ambulate at baseline, which improved to
350 and 360 m at 6 and 24 months. There were also significant and sustained improvements from baseline in both
BTT and DT patients in median MLWHF scores (by 40 and 42 U in DT patients, or 52% and 55%, at 6 and 24 months,
respectively), and KCCQ overall summary scores (by 39 and 41 U, or 170% and 178%).
Conclusions Use of a continuous flow LVAD in advanced heart failure patients results in clinically relevant improvements in
functional capacity and heart failure-related quality of life. (J Am Coll Cardiol 2010;55:1826–34) © 2010 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.052L
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009, accepted December 21, 2009.eft ventricular assist devices (LVADs) are becoming a
tandard therapeutic option for patients with advanced heart
ailure who are failing maximal medical treatment (1–12).
ewer generation LVADs have been developed with con-
inuous flow, rotary pump technology and are smaller and
uieter than older pulsatile volume displacement LVADs,
ith the capability of providing similar outputs of up to 10
/min (9–11). Continuous flow LVADs have been demon-
trated to improve morbidity and mortality in critically ill
atients awaiting transplantation while simultaneously re-
ucing adverse events (9–11).
Previous studies on pulsatile flow LVADs have demon-
trated significant improvements in quality of life measures
nd New York Heart Association (NYHA) functional class
ver time (5,13–17). Initial results from the continuous flow
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April 27, 2010:1826–34 Quality of Life With Continuous Flow LVADeartMate II LVAD (Thoratec Corporation, Pleasanton,
alifornia) trials also indicate improvements in quality of
ife and functional status (9–11,18) and stability or im-
rovements in domains of neurocognitive function (19).
owever, a detailed analysis in a large number of patients
hat describes the impact of continuous blood flow with
educed pulse pressure on long-term patient exercise per-
ormance and quality of life metrics has not been performed.
n this study, we report the impact of a continuous flow
VAD in over 650 patients with advanced heart failure on
uality of life and functional capacity for up to 24 months of
irculatory support.
ethods
he HeartMate II LVAD is a continuous flow device
onsisting of an internal axial-flow blood pump with a
ercutaneous lead that connects the pump to an external
ystem controller and power source (Fig. 1). Data presented
n this analysis are from the HeartMate II bridge to
ransplant (BTT) and destination therapy (DT) clinical
rials that were conducted between 2005 and 2009 at 38
enters in the U.S. (9–11). The authors had access to the
rimary data and attest to its accuracy. The HeartMate II
tudies were conducted in compliance with U.S. Food and
rug Administration (FDA) regulations for good clinical
ractices. The protocols were approved by the FDA and
ach participating center’s institutional review board.
Figure 1 HeartMate II Continuous Flow LVAD
Blood exits through the left ventricular apex and into the left ventricular assist
device (LVAD), which pumps throughout cardiac diastole and systole into the
ascending aorta. The LVAD pump is placed within the abdominal wall or perito-
neal cavity. A percutaneous lead connects the LVAD to an electronic controller
and battery packs, which are worn on a belt and shoulder holster, respectively. t
study subjects. Patients enrolled
n the BTT trial had NYHA func-
ional class IV heart failure symp-
oms and were listed as high pri-
rity for transplantation (United
etwork for Organ Sharing status
A or 1B). Patients with NYHA
unctional classes IIIB and IV
eart failure who were ineligi-
le for heart transplantation and
efractory to optimal medical
anagement were considered for
nrollment in the DT trial. Ex-
lusion criteria for both the trials
ncluded severe renal, pulmo-
ary, or hepatic dysfunction, ac-
ive uncontrolled infection, a me-
hanical aortic valve, aortic
nsufficiency, an aortic aneurysm,
ther mechanical circulatory sup-
ort (except an intra-aortic balloon pump [IABP]), and
echnical obstacles thought by the investigator to pose
xcessive surgical risk. Detailed characteristics and inclu-
ion/exclusion criteria of each of these patient cohorts have
een published elsewhere (9–11). All participating patients
rovided written informed consent.
aseline and post-implant assessments. Assessments of
unctional status and quality of life were obtained in patients
rior to LVAD implant (baseline) and at 1, 3, and 6 months
ost-implant for those enrolled in the BTT trial, and at 1,
, 6, 12, 18, and 24 months for patients in the DT trial.
re-Operative Baselineharacteristics in BTT and DT PatientsTable 1 Pre-Operative BaselineCharacteristics in BTT and DT Patients
Parameter
BTT
(n  281)
DT
(n  374) p Value
Age, yrs 50 13 63 12 0.001
Female, % 67 (24%) 102 (27%) 0.322
Ischemic etiology of
heart failure, %
121 (43%) 217 (58%) 0.001
LVEF, % 16.3 6.5 17.1 5.8 0.025
CI, l/min/m2 2.1 0.6 2.1 0.6 0.889
PCWP, mm Hg 25.4 7.9 23.9 8.3 0.021
Systolic BP, mm Hg 98.1 15.0 102.1 15.1 0.001
BUN, mg/dl 30.4 17.1 34.4 21.3 0.023
Creatinine, mg/dl 1.4 0.5 1.5 0.6 0.040
Total bilirubin, mg/dl 1.3 0.9 1.3 1.0 0.603
ALT, U/l 106 278 44 69 0.001
Na, mmol/l 134 5 135 5 0.002
CRT 135 (48%) 268 (72%) 0.001
Intravenous inotropes 252 (90%)* 289 (77%) 0.001
IABP 126 (45%) 78 (21%) 0.001
10% intolerant due to arrhythmias.
ALT  alanine aminotransferase; BP  blood pressure; BTT  bridge to transport; BUN  blood
rea nitrogen; CI  cardiac index; CRT  cardiac resynchronization therapy; DT  destination
Abbreviations
and Acronyms
CSS  clinical summary
score
IABP  intra-aortic balloon
pump
KCCQ  Kansas City
Cardiomyopathy
Questionnaire
LVAD  left ventricular
assist device
METS  metabolic
equivalent task score
MLWHF  Minnesota
Living With Heart Failure
NYHA  New York Heart
Association
OSS  overall summary
scoreherapy; IABP  intra-aortic balloon pump; LVEF  left ve
odium; PCWP  pulmonary capillary wedge pressure.ntricular ejection fraction; Na  serum
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Quality of Life With Continuous Flow LVAD April 27, 2010:1826–34NYHA functional class at each time period was assessed
ndependently by a physician, nurse, or other trained med-
cal staff not directly involved with the patient’s care at that
ime. Submaximal exercise performance was measured using
he 6-min walk test. Patients unable to walk at any time
eriod due to a medical condition (i.e., IABP in place; in
ntensive care unit on inotropes; orthopedic limitations) and
atients who refused to walk were excluded from this
nalysis.
Activity levels were assessed using metabolic equivalent
ask score (METs) in which patients were asked to describe
heir highest activity level during the reporting period, with
cores ranging from very low (1 METS  bedridden,
nable to care for self, unable to participate in any physical
ctivity), moderate (2 to 4 METS  walking 2 to 3 mph,
ight gardening, vacuuming or mopping the floor, golfing,
Figure 2 Changes in Functional Class Following LVAD
New York Heart Association (NYHA) functional class was determined by an indepe
tion therapy (DT) trials. Study inclusion criteria required NYHA functional class III t
significant in both trials (p  0.001).ainting walls), to very high (6 METS  dancing,
limbing stairs, stationary cycling [10 mph], heavy shov-
ling) (20).
Heart failure-related quality of life was assessed with
he Minnesota Living With Heart Failure Questionnaire
MLWHF) (21,22) and Kansas City Cardiomyopathy
uestionnaire (KCCQ) (23). The MLWHF questionnaire
ssesses the impact of heart failure and its treatment on key
hysical, emotional, social, and mental dimensions of qual-
ty of life. The KCCQ quantifies physical function, symp-
oms (frequency, severity, and recent change), social func-
ion, self-efficacy, and knowledge, and quality of life. An
verall summary score (OSS) is derived by combining scores
n each domain. A clinical summary score (CSS) is derived
y combining the physical function and symptoms scores.
or both KCCQ summary scores, a higher value represents
clinician at the time points shown in the bridge to transplant (BTT) and destina-
mptoms at baseline. NYHA functional class improvements were statisticallyndent
o IV sy
a
i
S
t
d
f
i
s
b
w
m
h
c
e
f
s
a
(
R
B
T
b
w
p
p
a
D
m
i
T
t
d
a
w
(
F
s
t
N
s
N
s
o
f
s
N
s
e
B
6
a
c
p
w
(
1829JACC Vol. 55, No. 17, 2010 Rogers et al.
April 27, 2010:1826–34 Quality of Life With Continuous Flow LVADbetter quality of life, whereas a lower score reflects
mproved quality of life with the MLWHF questionnaire.
tatistical analysis. Differences between baseline charac-
eristics of BTT and DT patients were determined for
escriptive purposes only, with independent samples t test
or continuous variables or the Fisher exact test for categor-
cal variables. No adjustments were made on functional
tatus or quality of life data based on baseline differences
etween cohorts. For continuous variables of the 6-min
alk test, MLWHF, and KCCQ, linear mixed effects
odeling was used to determine statistical significance. Post
oc comparisons were performed using the Scheffe test. For
ategorical variables (NYHA functional class, activity lev-
ls), mixed effects ordinal regression was performed to test
or significant changes over time. The level of statistical
ignificance was set at p  0.05. All statistical comparisons
re 2-sided. Statistical analyses were done using Systat
Cranes Software, Chicago, Illinois) and MIXOR (24).
esults
aseline clinical characteristics of patients are shown in
able 1. The BTT patients were younger and more likely to
e treated with intravenous inotropic agents or an IABP,
hereas the DT patients had a higher systolic blood
ressure and worse renal function. More than 75% of
atients in both groups were receiving intravenous inotropes
t baseline, and 45% of patients in the BTT and 21% in the
T trials were supported with an IABP at study enroll-
Figure 3 Submaximal Exercise Performance After LVAD
Mean 6-min walk distances in the BTT and DT trials are shown over time. Ascertai
number of observations (n) at each time point is shown at the bottom of the figure
abbreviations as in Figure 2.ent. Cardiac resynchronization therapy (CRT) was used
n 48% and 72% of the BT and DT patients, respectively.
he number of patients available for testing varied at each
ime interval because of transplantation, death, study with-
rawal, device explantation, availability of study personnel,
nd scheduling. Overall survival and outcomes associated
ith the BTT and DT trials have been published previously
9–11).
unctional status. NYHA FUNCTIONAL CLASS. Figure 2
hows the change in NYHA functional class over time for
he BTT and DT cohorts. At baseline, most patients had
YHA functional class IV symptoms, and after 1 month of
upport, 59% (BTT) and 47% (DT) of patients improved to
YHA class I or II, increasing further after 6 months of
upport to 82% (BTT) and 80% (DT). Approximately 80%
f DT patients remained in NYHA functional class I or II
rom 6 through 24 months. With respect to their baseline
cores, patients achieved highly significant improvement in
YHA functional class at all study intervals for both the
tudy groups (p  0.001). There was no significant differ-
nce in the improvements seen in NYHA class between
TT and DT patients.
-MIN WALK TEST. At baseline, a relatively small percent-
ge of patients in both the BTT (14%) and DT (34%)
ohorts were able to perform the 6-min walk test. For
atients who performed the test, average baseline 6-min
alk distance was 214  125 m (BTT) and 204  150 m
DT), which increased significantly at 6 months to 372 
of baseline 6-min walk distance was limited to patients able to ambulate. The
0.05 compared with baseline. LVAD  left ventricular assist device; othernment
. *p 
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Quality of Life With Continuous Flow LVAD April 27, 2010:1826–3499 m and 350  198 m for BTT and DT, respectively
Fig. 3). The 6-min walk distance was maintained
hroughout the follow-up period in the DT patients and
as 360  210 m at 24 months. Overall, there was a
tatistically significant improvement over time at all test
ntervals for both study groups (Fig. 3). In DT patients,
he mean walk distance from baseline to 24 months
ncreased by more than 150 m.
ATIENT ACTIVITY SCORES. Figure 4 shows the percentage
f patients with each activity level at each time point. At
aseline, 93% of patients in the BTT group, and 96% of the
atients in the DT group described their level of activity as
ither low or very low. By 6 months, 68% of patients in the
TT group and 62% in the DT group described their
Figure 4 Patient-Reported Exercise Ability Following LVAD
Serial assessment of metabolic equivalent task score (METs). At baseline, 90%
months, approximately two-thirds of patients described their level of function as mctivity levels as moderate, high, or very high, an improve- (ent that was highly significant (p  0.001). After 6
onths, the level of improvement stabilized in the DT
ohort, and 60% of the patients described their activity
evels as moderate, high, or very high at 24 months.
UALITY OF LIFE QUESTIONNAIRES. MLWHF scores de-
reased over time, indicating an improvement in quality of
ife (Fig. 5, Table 2). When compared with baseline scores
n patients with paired comparisons, highly significant (p 
.001) median improvement in scores of10 and13 points
ere seen at 1 month in the BTT and DT groups, followed by
ontinued improvements of 29 and 40 points at 6 months
f support. The median percent improvement at 6 months for
he BTT and DT groups were 38% and 52%, respectively. At
4 months, there was a median improvement of 42 points
ients in both trials described their level of function as low or very low. At 6
te to very high (p  0.001 vs. baseline). LVAD  left ventricular assist device.of pat
odera55%) compared with baseline.
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April 27, 2010:1826–34 Quality of Life With Continuous Flow LVADKCCQ overall summary and clinical summary scores also
mproved during HeartMate II support (Fig. 6, Table 2).
he median KCCQ OSS showed significant early improve-
ents by 14 and 16 points at month 1 for BTT and DT
atients compared with baseline, with 28 and 39 point
mprovements at 6 months of support. After 6 months, the
CCQ scores remained stable with a median improvement
n DT patients of 41 points at 24 months compared with
aseline. Similar improvements were observed in the
CCQ CSS. At 6 months post-implant, 79% of BTT and
2% of DT patients with paired data had achieved a
Figure 5 Changes in Quality of Life: MLWHF
Changes in quality of life assessed with the Minnesota Living With Heart Failure (M
improved quality of life. Bars indicate 25th, 50th, and 75th percentiles, whiskerslinically meaningful improvement of 5 points in their fiCCQ OSS compared with baseline. Similar results were
ound for the KCCQ CSS.
iscussion
he current study demonstrates that patients with advanced
eart failure who have marked functional limitations and
mpaired quality of life derive significant improvements in
ubmaximal exercise performance and heart failure-related
uality of life following implantation of a continuous flow
VAD. Similar improvements were seen in both the BTT
nd DT patients, 2 overlapping populations typically de-
) Questionnaire are shown. Lower values signify
te 5th and 95th percentiles. *p  0.05 compared with baseline.LWHF
indicaned by age and severity of comorbidities. Although trial
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Quality of Life With Continuous Flow LVAD April 27, 2010:1826–34esign limited follow-up to 6 months in the BTT cohort,
he DT trial allowed more prolonged observation of changes
n patient functionality and quality of life. The early
mprovements in exercise performance and quality of life
emonstrated in both patient groups were sustained and
howed no evidence of decline through 2-year follow-up.
The current report is the largest study of advanced heart
ailure patients with serial measurement of functional ca-
acity and quality of life metrics following a mechanical
ntervention. The poor pre-implant exercise performance
nd quality of life scores despite optimal medical and
lectrical therapies, including CRT when appropriate, high-
ight the limitations of currently utilized treatments for
atients with stage D heart failure. Recent studies have
ocumented 1-year survival rates of 73% in BTT patients
10) and 1- and 2-year survival rates of 68% and 58% in DT
atients supported with a continuous flow LVAD (11).
owever, a majority of patients with advanced heart failure
xpress a strong desire for improvements in quality of life
nd functionality, even at the expense of longevity (25,26).
he totality of data from the HeartMate II trials suggests
hat these patients who have a predictably high short-term
ortality and symptoms with minimal activity or at rest may
e able to achieve both mortality reduction and improved
uality of life following treatment with a continuous flow
VAD. Therapies targeted to the stage D heart failure
opulation must focus on patient-centric outcomes that
uality of Life Improvements Over Time in Patients Implanted WithTable 2 Quality of Life Improvements Over Time in Patients Imp
Month
HMII BTT
n
Paired Changes
Mean  SD Median [25th, 75th]
% Impro
of Me
MLWHF
1 167 12 27 10 [28, 4] 1
3 126 24 31 30 [47,4] 3
6 87 28 28 29 [50,9] 3
12 0 — — —
18 0 — — —
24 0 — — —
KCCQ OSS
1 172 13 25 14 [3, 29] 5
3 132 22 26 20 [9, 42] 7
6 90 27 28 28 [7, 45] 10
12 0 — — —
18 0 — — —
24 0 — — —
KCCQ CSS
1 170 12 27 11 [6, 31] 3
3 132 21 28 21 [4, 42] 5
6 90 25 31 24 [8, 43] 6
12 0 — — —
18 0 — — —
24 0 — — —
alues are the mean  SD and median [25th, 75th percentiles] of paired changes at each time p
CSS  clinical summary score; HMII  HeartMate II; KCCQ  Kansas City Cardiomyopathy Quenclude reduction of symptom burden and improved ability uo perform the activities of daily living. This study estab-
ishes a benchmark against which other medical and device
herapies can compare.
The 6-min walk test is an accepted method for assessing
unctional capacity that has good reproducibility, is well
olerated, and is very relevant to daily activities (27). This
est has been used extensively in heart failure clinical trials
28). The relative improvements in exercise performance
een with the continuous flow LVAD can be put into
erspective by comparison to the outcomes of patients
nrolled in CRT trials. A prior study supporting the use of
RT in patients with NYHA functional class III to IV
eart failure symptoms established that a 39-m improve-
ent in 6-min walk distance can be considered clinically
eaningful (29). A retrospective analysis of patients with
YHA functional class IV symptoms treated with CRT from
he COMPANION (Comparison of Medical Therapy, Pac-
ng, and Defibrillation in Chronic Heart Failure) trial demon-
trated a statistically significant 46-m increase in 6-min walk
istance with 78% experiencing 1 functional class improve-
ent (30). In contrast, LVAD-treated patients in this study
ho were able to complete a 6-min walk test prior to device
mplantation had a 146-m increase in mean walk distance at 6
onths (DT group), and more than 80% of patients had 2
unctional class improvements (DT group). Additionally, most
atients reported significant increases in daily functional capa-
ilities as indicated by moderate activity levels or higher based
HMIId With the HMII
HMII DT
n
Paired Changes
t
Mean  SD Median [25th, 75th]
% Improvement
of Median
241 17 31 13 [40, 4] 17%
231 35 28 37 [58,17] 48%
209 39 27 40 [60,20] 52%
177 39 30 41 [62,17] 53%
126 39 25 42 [57,22] 55%
82 41 25 42 [57,20] 55%
242 17 26 16 [1, 35] 70%
232 35 24 34 [19, 53] 148%
211 39 24 39 [20, 58] 170%
181 40 25 42 [24, 61] 183%
129 41 24 38 [22, 61] 165%
89 42 23 41 [25, 60] 178%
240 15 27 13 [3, 34] 41%
231 32 25 32 [14, 50] 100%
210 37 25 36 [17, 55] 113%
181 36 28 39 [18, 57] 122%
129 37 27 34 [18, 61] 106%
89 38 26 35 [20, 55] 109%
mpared with baseline. Also shown are the percent improvements of the median from baseline.
ire; MLWHF  Minnesota Living With Heart Failure; OSS  overall summary score.thelante
vemen
dian
3%
9%
8%
4%
7%
8%
0%
7%
5%pon estimated METs.
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April 27, 2010:1826–34 Quality of Life With Continuous Flow LVADThe first-generation pulsatile LVADs delivered blood
ow in a manner similar to the native heart. Once the device
as full, pump systole resulted in a normal stroke volume of
0 to 80 ml. Previous studies with these devices have shown
mproved exercise capacity (31,32), functional status, and/or
uality of life with LVAD support relative to medical
herapy (5,14) and in serial testing over time (13,15–17). A
nique aspect of the continuous flow LVADs is reduction of
he pulse pressure that is dependent upon the speed at
hich the device is run. At higher speeds, the device can
nload the ventricle completely, with corresponding reduc-
ions in pulse pressure. In clinical practice, the continuous
ow LVADs are commonly set at speeds that provide 5 to
l of flow with a detectable, but reduced, pulse pressure.
aft et al. showed substantially reduced pulse pressure with
ean systolic and diastolic blood pressures of 98/77 mm Hg
n patients with continuous flow LVADs compared with
16/64 mm Hg for patients with pulsatile flow LVADs
fter 3 months of support, but no difference in exercise
apacity (31). The impact of long-term reduced pulsatility
n peripheral muscle function and subsequent functional
apacity remains largely unexplored. Coupled with the
emonstrated improvements in exercise performance, it may
Figure 6 Changes in Quality of Life Assessed With the KCCQ
Kansas City Cardiomyopathy Questionnaire (KCCQ) scores versus left ventricular a
75th percentiles, whiskers indicate 5th and 95th percentiles. *p  0.05 comparee reasonably assumed that alterations in flow characteristics typically seen with continuous flow LVADs do not nega-
ively impact peripheral muscle function, at least through
he first 24 months of support.
A 5-point change in both the MLWHF score and the
CCQ has been previously determined to be clinically
eaningful (21–23,33). Both patient cohorts in our analysis
xperienced an early 10-point improvement in median
LWHF score 1 month after LVAD implantation, with
urther improvement in MLWHF scores observed through-
ut the observation periods. In fact, at 24 months, DT
atients had a 42-point paired improvement in quality of
ife score assessed by this tool, and a 41-point paired
mprovement using the KCCQ instrument.
One limitation of this study is that both MLWHF and
CCQ represent heart failure-related quality of life mea-
ures, whereas a wider range of domains of quality of life
uch as those reported by Grady et al. (13) would provide a
ore complete assessment. Other limitations include a
ariable number of patients studied at each time interval due
o such factors as death, transplantation, staff availability, or
cheduling, and thus there could be ascertainment bias due
o exclusion of sick patients. This may be partially offset by
imultaneous exclusion of healthy patients who underwent
evice support duration are shown. Bars indicate 25th, 50th, and
baseline. CSS  clinical summary score; OSS  overall summary score.ssist d
d withransplantation. Paired analyses of improvements were per-
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Quality of Life With Continuous Flow LVAD April 27, 2010:1826–34ormed where possible and confirm findings with the overall
opulation as a whole. Also, there are incomplete data on
he 6-min walk test related to exclusion of patients who
ere unable to walk at baseline due to medical issues, most
f which were related to the severity of heart failure,
ncluding bedridden condition, presence of an IABP, or
notropes. Exclusion of these patients from the analysis may
nderestimate the overall improvement associated with the
herapy. An analysis of the potential effects of patients with
issing data is provided in the Online Appendix.
onclusions
eartMate II LVAD support in both the bridge to trans-
lant and destination therapy applications results in early,
ustained, and clinically meaningful improvements in func-
ional capacity and heart failure-related quality of life.
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